EGFR and non-small cell lung carcinoma: EGFR mutation is a marker for target therapy of NSCLC, but its prognostic value is debated.31 We, and others,31 found that for the LUAD patients of GSE13213 who did not receive ACT, their overall survival outcomes were similar whether or not their EGFR harbored a mutation (Figure S3A).